Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Bullboard Posts
Comment by 2b7f6fabon Oct 09, 2017 9:04pm
186 Views
Post# 26793002

RE:RE:Share Price

RE:RE:Share Price Um...I doubt it.  30 million warrants outstanding with an exercise price at 54 cents and under amounts to less than $15 million.  At some point, hopefully in the very near future a news release is going to come out that will wake the market up.  Probably a news release from UHN indicating significant efficacy or HC/FDA PH2 approval, Expedited Review, JV etc.  $15 million is nothing, the market will blow through that with the very first trade once there is a whif of efficacy in the air.

To borrow a phrase from bencro-  "You lack understanding of the market you're invested in"

LAZERR00 wrote:
That's cuz the stock is diluted so yeah, alot of shares have to move


Bullboard Posts